|
|
HER3 in NSCLC " Navigating New Frontiers in Targeted Therapy
In patients with non-small cell lung cancer (NSCLC), human epidermal growth factor receptor 3 (HER3) is associated with both advanced disease and resistance to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)"directed therapies. Although there are therapeutic options targeting EGFR (HER1) and HER2, the potential of HER3 as an anti-cancer target has been largely overlooked. Overexpression of HER3 in most patients with NSCLC positions it as an appealing therapeutic targ... |
|
|
Bridging Gaps, Optimizing Treatment in Adults With LC-FAODs
In this 45-minute, case-based, modular activity, Sandra van Calcar, PhD, RD, LD, and Jerry Vockley, MD, PhD, address key topics, including disease presentation, historical treatment, emerging treatment with triheptanoin, and nutritional planning specific to patients with LC-FAODs. Triheptanoin is an odd-carbon MCT designed to bypass the metabolic block in LC-FAODs, recently approved as an alternative treatment option. The faculty discuss the safety and efficacy of triheptanoin and their real-w... |
|
|
Biosimilars in Osteoporosis: Highlights from the ASBMR
Biosimilars are large, complex molecules made from living organisms that are highly similar to their reference biologic and are administered in the same way, with the same strength and dosage, and clinically meaningful differences in safety, purity, and potency.
Incorporating biosimilars into the management of osteoporosis, known as a silent chronic disease responsible for 13 million fragility fractures worldwide, provide a more affordable version of osteoporosis medication, and an alternat... |
|